This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join BNMS | Print Page | Contact Us | Sign In
Supply Updates from Industry
Share |
Supply Updates from Industry

Curium Contingency Plan

Select the link below to view

Curium Pharma UK EU Exit Contingency Oct 2020


IRE supplies a first commercial batch of LEU-based Mo-99

The Institute for radioelements (IRE), one of the leaders in the production of Molybdenum-99 (Mo-99), the most widely used radio-isotope in nuclear medicine for diagnosis, announced today that the company produced its first commercial Mo-99 Low Enriched Uranium (LEU) batch for the US market.

This conversion to LEU represents a key milestone for IRE in the global commitment to end the civil use of High Enriched Uranium (HEU) for the production of Mo-99 medical isotopes. This demonstrates its unique capacity to carry out advanced R&D activities while maintaining during the last two years its highest production output to serve the global market during temporary or unplanned outages of some alternative suppliers of medical radioisotopes. It achieves the first step of the complex development of an entirely new industrial process to supply healthcare professionals with Mo-99. This conversion will include very soon the production process for Iodine -131 (I-131), essential and irreplaceable radionuclide for thyroid cancer treatments, based on LEU. Despite the additional burden induced by the lockdown caused by the COVID-19 crisis, our teams could maintain and complete their planning to receive the authorization from the FANC, the Federal Agency for Nuclear Control in Belgium. Conversion to LEU will positively impact Safety and Security on site, two components inseparable of our IRE activity, since this new LEU production flow takes place in refurbished installations that bring many advantages in terms of nuclear safety and nuclear security for our teams.

Read more


Curium Delivery Distancing Measures

Please find below important communication with regards to the delivery & distancing measures of radioactive goods.

Read here


Curium Covid-19 letter

The following link is a communication regarding Covid-19 from Curium

Curium Communication Letter


Curium Renocis Communication Letter

The following link is a communication regarding the availability of RENOCIS
Curium are waiting on MHRA approval to import DMSA which hasn’t been received as yet, it is highly unlikely, but if they do not approve the import Curium will not be able to supply DMSA

Renocis Communication Letter


Curium Brexit update

See the latest information from Curium regarding Brexit.

Brexit update letter


Curium Brexit update and Surcharge Letter

Please find attached an updated Brexit Communication letter plus a letter with regards to a Brexit surcharge.

Brexit update letter

Surcharge letter


Advanced Accelerator Applications Brexit Letter

Please find attached a letter regarding the delivery of Lutathera in the run up and immediately after Brexit

Brexit Letter


Curium Brexit Contingency Plan further update

Please find attached the latest communication regarding Curium's Brexit Contingency plans.

Curium Brexit update


I131 T-Caps production line maintenance shut down period

The Curium production facility at Petten is performing maintenance and an upgrade of its I-131 Therapy Capsule production line during the first 2 weeks of July.
This will mean a full shut down of the line from Friday 28th June until Thursday 11th July.

Press Release


Blue Earth press release

Blue Earth Diagnostics continues to expand access to Axumin (fluciclovine (18F)) in Europe

Blue Earth Diagnostics continues to expand


Curium Brexit update - 12 April 2019

Please find attached the latest communication regarding Curium's Brexit Contingency plans.

Due to the recent approval of an extension until 31st October, Curium will revert back to Road freighting each day as of Sunday 14th April.

Customer Services in Portsmouth will work directly with customers to check their deliveries for next week and ensure they have the correct activity arriving on the correct day.

Curium Brexit update


Curium Communication - Brexit Contingency

Please find an update as of 18th March on behalf of Curium Pharma UK Ltd

Curium Brexit update


Brexit Update From Curium - Updated

Please find the most recent information surrounding our Brexit contingency plans

Feb 2019 Curium Brexit Contigency updated


Important Communication - LyoMAA & Pulmocis

Please find an important communication in relation to products LyoMAA & Pulmocis.

300119 Curium Pulmocis update


LyoMAA Important Update

Please find an important update with regards to LyoMAA

Lyomaa Curium December 2018


Dec 2018


Communication From Curium

Please find a letter on behalf of Curium regarding DTPA for GFR measurement
Although we know DTPA is not an exact subsitute for CR-51, it is the only available alternative in the market.

Curium Technescan DTPA for GFR measurement Dec18

Dec 2018


Molybdenum And UTK Availability

Please find an update below on the Molybdenum and UTK availability from Curium's production site in Petten

Customer letter



Communication On Behalf Of Curium

Please find below communication on behalf of Curium concerning their Brexit contingency plans

Curium Brexit Contingency Planning




© 2013 BNMS unless otherwise stated.
The BNMS is a registered as a company in England and Wales with number 08082786.  The BNMS is a charity governed by the rules of the Charity Commission for England and Wales - Registered Number 1150234.  Registered Office: The Royal College of Physicians, 11 St. Andrew's Place, Regent's Park, London NW1 4LE.
The British Nuclear Medicine Society is not able to give specific clinical advice to members of the public. If you are concerned about your scan or therapy please seek the opinion of a nuclear medicine clinician where you were seen or the clinician who referred you to the department or your GP.
Enquiries related to issues such as internships and work experience opportunities, should be directed to the relevant professional body e.g., for radiologists, this will be the Royal College of Radiologists.